title: [Should patients with severe sepsis be treated with activated protein C?].
abstract: BACKGROUND
  Xigris (recombinant human activated protein C) has recently been introduced as a treatment for severe sepsis following a large multicentre trial (the PROWESS trial).
  
  
  METHODS
  Critical review of the original paper, follow-up studies and commentaries, and subgroup analyses from the US Food and Drug Administration.
  
  
  RESULTS
  Changes in trial design after the start of the trial as well as inconsistent results in two phases of the trial make interpretation difficult. The overall trial results indicate a small benefit from treatment with activated protein C. However, subgroup analysis reveals that several groups of patients appeared to have little benefit. The drug may have severe and potentially lethal side effects in some patients.
  
  
  CONCLUSIONS
  Although activated protein C may have beneficial effects in some patients with severe sepsis, the effect on different subgroups of patients remains to be clarified. We conclude that there is at present insufficient documentation for a recommendation of activated protein C in patients with severe sepsis.
authors.affiliation: Anestesiavdelingen,Rikshospitalet, 0027 Oslo. j.h.laake@basalmed.uio.no
authors.forename: Jon Henrik
authors.initials: JH
authors.lastname: Laake
authors.forename: Jon Bragi
authors.initials: JB
authors.lastname: Bergmann
authors.forename: Fridtjov
authors.initials: F
authors.lastname: Riddervold
authors.forename: Arvid
authors.initials: A
authors.lastname: Bjørneklett
authors.forename: Pål
authors.initials: P
authors.lastname: Aukrust
authors.forename: Stig S
authors.initials: SS
authors.lastname: Frøland
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; D006493:Heparin; C421124:drotrecogin alfa activated